Roche Not Alarmed by Obesity Drug's Side Effects, R&D Head Says - SWI swissinfo.ch
Roche Holding AG remains unconcerned about side effects in a small study of its weight-loss shot CT-388, despite shares tumbling due to early release of side effect details. The company emphasizes no patients stopped treatment in the trial, and its other weight-loss candidate, CT-966, could be 'best in class.' Roche is focusing on five core therapy areas and diversifying in oncology, actively seeking partners in promising fields like antibody-drug conjugates.
Reference News
Roche Holding AG remains unconcerned about side effects in a small study of its weight-loss shot CT-388, despite shares tumbling due to early release of side effect details. The company emphasizes no patients stopped treatment in the trial, and its other weight-loss candidate, CT-966, could be 'best in class.' Roche is focusing on five core therapy areas and diversifying in oncology, actively seeking partners in promising fields like antibody-drug conjugates.